Navigation Links
Alpina® Total Knee System

ProductsAlpina® Total Knee System
Company Biomet Orthopedics, Inc
Item Alpina® Total Knee System
Features 
  • Available in 5 sizes.
  • Available in right and left.
  • Constructed of cobalt chromium alloy.
    • Description The design and concept of the Alpina knee allows the choice of implanting a PCL retaining or a posterior stabilized prosthesis intraoperatively, right up until the definitive implants are to be put in place.
    Info Biomet Orthopedics, Inc
    Customer Service: (800) 348-9500
    Web site: http://www.biomet.com

    Related medicine products :

    1. Laserex Tango M (Total Mobile Version)
    2. Bilirubin, Direct & Total
    3. Bilirubin Total Reagent
    4. Total Bilirubin Reagent
    5. Total Protein
    6. Total Protein Reagent
    7. Total Protein Reagent Set
    8. Iron Total (TIBC)
    9. Iron (Total/Ferene)
    10. Cholesterol, Total
    11. Total Internal Reflection Fluorescence Microscopy
    Other Medicine News:Health News:Partnership for a Drug-Free America(R) Responds to 2008 Monitoring the Future Study Results 2Health News:Partnership for a Drug-Free America(R) Responds to 2008 Monitoring the Future Study Results 3Health News:Betty White's Video States Support for Funding Humane Research to Help Pets and Wild Animals - Actress is 40-Year Champion of Morris Animal Foundation 2Health News:Hallmark Hall of Fame Collaboration with Patient Organization Equals Extraordinary Success 2Health News:Playing Video Games May Boost Older Brains 2Health News:Playing Video Games May Boost Older Brains 3Health News:Cancer drugs in the pipeline 2Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 2Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 3Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 4Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 5Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 6Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 7
    Breaking Medicine Technology:Royalty Pharma Announces that Alexander von Perfall Joins Management Team 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 3ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 57495 1SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 57495 2SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 57495 3SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 57495 4SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 57495 5SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 57495 6African Americans at Significantly Higher Risk of DVT or Blood Clots 57491 1African Americans at Significantly Higher Risk of DVT or Blood Clots 57491 2African Americans at Significantly Higher Risk of DVT or Blood Clots 57491 3African Americans at Significantly Higher Risk of DVT or Blood Clots 57491 4Rigel Announces Pricing of Public Offering of 13 000 000 Shares of Common Stock 14119 1Rigel Announces Pricing of Public Offering of 13 000 000 Shares of Common Stock 14119 2